Harrow (HROW) Expected to Post Earnings on Monday

Harrow (NASDAQ:HROW – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Harrow to post earnings of $0.1944 per share and revenue of $98.59 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Harrow (NASDAQ:HROW – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). The firm had revenue of $70.66 million for the quarter, compared to analysts’ expectations of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%. On average, analysts expect Harrow to post ($0.02) EPS for the current fiscal year and $2.02 EPS for the next fiscal year.

Harrow Stock Performance

Shares of NASDAQ:HROW opened at $26.89 on Friday. The business has a 50-day moving average of $31.63 and a two-hundred day moving average of $37.91. The firm has a market capitalization of $1.01 billion, a PE ratio of -26.89 and a beta of 0.18. The company has a debt-to-equity ratio of 19.70, a current ratio of 2.24 and a quick ratio of 2.08. Harrow has a 12 month low of $25.76 and a 12 month high of $54.85.

Insiders Place Their Bets

In related news, insider Amir Shojaei sold 11,250 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $40.00, for a total value of $450,000.00. Following the completion of the sale, the insider directly owned 11,250 shares in the company, valued at approximately $450,000. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HROW. BTIG Research reiterated a “buy” rating and set a $63.00 target price on shares of Harrow in a report on Wednesday, October 7th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Friday, October 16th. Finally, Leerink Partners assumed coverage on shares of Harrow in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Harrow currently has an average rating of “Moderate Buy” and a consensus target price of $66.17.

Read Our Latest Stock Report on Harrow

Harrow Company Profile

(Get Free Report)

Harrow, Inc is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription therapies for eye care. The company’s portfolio addresses conditions and procedures involving the ocular surface, anterior segment, and retina, with products intended for use by ophthalmologists and other eye-care professionals.

Harrow’s commercial products include VEVYE, a cyclosporine ophthalmic solution for the treatment of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used for ocular surface anesthesia during ophthalmic procedures.

Read More

Earnings History for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.